The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06592430

Enrollment

2000

Registered

2024-09-19

Start date

2024-10-01

Completion date

2026-10-01

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The use of smartphone-based WeChat applications offers significant advantages in cancer patient education, rehabilitation monitoring, and postoperative symptom management. Through the WeChat platform, patients can access health education materials, engage in online consultations, and interact with doctors and other patients at any time. This ongoing education and psychological support help alleviate patient anxiety and improve their quality of life. This study aims to conduct a prospective observational study in our hospital to explore the impact of WeChat communication on the prognosis of patients with different histological types and stages of lung cancer.

Interventions

OTHERPatients diagnosed with lung cancer use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers

OTHERPatients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* (1) Lung cancer patients receiving treatment at Shanghai Pulmonary Hospital (2) ECOG performance status of 0-2 (3) No other serious internal medical conditions (such as severe heart failure, hypertensive crisis, diabetic ketoacidosis, severe liver or kidney impairment, etc.) (4) No history of other malignant tumors in the past 5 years, and no detection of other tumor history during follow-up after lung cancer diagnosis (5) Relevant pathological results

Exclusion criteria

* (1) Patients refused enrollment in this study; （2）Patients refused follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival (OS)	5 years	It is defined as the time (years) frome enrollment to death of participants due to an cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date.

Contacts

Primary ContactPeng Zhang, PhD

zhangpeng1121@tongji.edu.cn021-65115006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026